3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Myeloid
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroblastoma
60
Central Nervous System Neoplasms
39
Brain Neoplasms
34
Medulloblastoma
26
Astrocytoma
15
Rhabdoid Tumor
12
Glioblastoma
12
Ependymoma
12
Sarcoma
10
Glioma
9
Testicular Neoplasms
8
Oligodendroglioma
7
Choroid Plexus Neoplasms
7
Teratoma
6
Optic Nerve Glioma
6
Neuroectodermal Tumors, Primitive, Peripheral
6
Gliosarcoma
6
Testicular Germ Cell Tumor
5
Retinoblastoma
5
Neuroectodermal Tumors, Primitive
5
Neoplasms
5
Lymphoma
5
Recurrence
4
Ovarian Neoplasms
4
Ganglioneuroblastoma
4
Familial ependymoma
4
Carcinoma, Renal Cell
4
Spinal Cord Neoplasms
3
Rhabdomyosarcoma
3
Osteosarcoma
3
Interventions
Cyclophosphamide
2
pembrolizumab
1
molibresib
1
fludarabine phosphate
1
fludarabine
1
etoposide phosphate
1
Temozolomide
1
Sirolimus
1
Pemetrexed
1
Oncolytic Virotherapy
1
Mesna
1
Etoposide
1
Craniotomy
1
Celecoxib
1
Carboplatin
1
ADI PEG20
1
3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione
1
1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Etoposide
×
CNS
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled